STALICLA’s Post

ISCTM 2023 Autumn Conference joint day with European College of Neuropsychopharmacology (ECNP) held on 5-7 October 2023 in Barcelona, Spain. It was a real pleasure to participate as panelist during the discussion at Session 3: Are our clinician rated psychopathology measures fit for purpose decades later? Chairs: Nina Schooler Celso Arango Stephen Marder Participants: koen demyttenaere, Eduard Vieta, Vikas Mohan Sharma and Alex Cohen. "Most of the measures of psychopathology that we currently use have been in place for decades and some for more than half a century. (...) However, these older measures have not been informed by recent advances in the understanding of psychopathology and all of them rely on a subject’s recollection of symptoms during a defined time period." The recognition of the weakness of this existing instruments made by experts, is the first step towards its improvement, opening the room to innovative solutions. It is relevant to stablish what is needed to be measured in clinical research and to develop the best tool for the context of application of any new treatment. All this relevant work needs to be done years in advance when planning for a new drug development. It was a great opportunity to be the voice of the Thematic Working Group at the ECNP focused on Outcomes Research in Early-phase Clinical Trials, and express the need to follow standard processes and that pre-competitive approaches nowadays represent an optimal scenario to work for advancing in the science of outcomes for clinical trials in neurosciences. It is always a great experience and pleasure to participate in @ISCTM and @ECNP working groups and events. #COA #ClinicalTrials #Neurosciences #CNS #psychiatry #neurology

🚨 New publication research led by Tobias Böckers et al explores synaptic function in SHANK-associated conditions like autism spectrum conditions, schizophrenia, and Phelan-McDermid syndrome. Using STED microscopy, the team investigated the nanostructural changes in synaptic proteins within both human and murine brain tissue. Their findings revealed distinct shape-profiles of the postsynaptic scaffold across different brain regions and genotypes, providing crucial insights into the spatial and molecular organization of subsynaptic domains under SHANK3-deficient conditions. 🌟 This research establishes a solid foundation for future studies, paving the way for deeper exploration of synaptic properties in neuropsychiatric conditions. 👀 Read the full article published in Molecular psychiatry here: https://lnkd.in/ePmGavXe #Neuroscience #ASC early #WKNDreading

🔦 Medaffcon is Preparing to Conduct RWE Studies in #Neurology and #Psychiatry 💡 In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, #RWE studies (Real World Evidence). 🧠 In neurology and psychiatry, new drugs have not been developed as frequently as in fields like cancer treatment. “The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila.  Mattila has worked, e.g., at the #Neuroscience Center of the University of Helsinki, researching Alzheimer’s disease.  ➡ Read more about the article ➡ https://lnkd.in/dxTPM7NJ #pharmaceutical #scandinavia

Acta Neuropsychiatrica announces a call for submissions to a special issue titled "Progress in Immunopsychiatry," dedicated to showcasing the latest advancements in the field. https://lnkd.in/eiB4xPzS 💡 Immunopsychiatry has significantly advanced our understanding of the link between the immune system and mental health, revealing how immune dysregulation can impact psychiatric disorders. 📊 This issue aims to cover a wide range of topics, from preclinical science to cutting-edge overviews of new drugs in clinical trials to comprehensive epidemiological studies, underscoring the relevance in the pathophysiology of neuropsychiatric disorders. We invite researchers to contribute original articles and review papers that provide fundamental insights into both clinical and preclinical studies, with a particular emphasis on novel findings in disease mechanisms. Final submissions are due August 1st 2024 on the Journal submission site. Express interest in the issue here: https://lnkd.in/dv22mxA8 📝 Check out the website for more information! #Psychopharmacology #Neuropsychopharmacology #Neuropsychiatric #ScientificJournal #Neuroimmunology #ClinicalStudies #PreclinicalResearch #Gutbrainaxis #Neuroscience #ResearchOpportunity

🎉 Congratulations to Dr. Sylvain Lehmann and their team for their outstanding publication in the Journal of Neurology, Neurosurgery, and Psychiatry! This study provides vital early evidence that elevated pTau217 levels can predict progression from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD); individuals who transitioned from MCI to AD exhibited a 70% higher pTau217 level. Prediction of conversion to AD will be a valuable insight for optimizing individualized treatment plans. The authors also found that renal function (eGFR, creatine) had minimal impact on plasma pTau217 performance, but did affect pTau181 performance. The robustness of pTau217 performance was attributed to the high fold change between amyloid-negative and amyloid-positive states for plasma pTau217. This study is a key early step in understanding how to predict progression from MCI to Alzheimer’s disease, which will have profound implications for optimizing clinical care of this difficult disease. #AlzheimersResearch #JournalPublication #Neurology #Neurosurgery #Psychiatry #MedicalResearch Read more: https://lnkd.in/gRH4CvKj

𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐢𝐧 𝐍𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 Treating #CNS disorders is a challenging endeavor. Despite significant investments, many drugs falter in late-stage clinical trials, leaving sponsors with limited options, physicians in a quandary over treatment decisions, and patients without effective therapies. Enter digital biomarkers—tools that capture physiological and behavioral data with the potential to 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐂𝐍𝐒 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞. 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫𝐬 𝐜𝐚𝐧: ◾ Enhance clinical development ◾ Provide physicians with actionable insights ◾ Offer patients more effective treatments Read Sheryl Caswell's, Monument Therapeutics insightful article on the transformative benefits of digital biomarkers in neuroscience. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/gMHcvGFh 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/dd4w2vnF 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gv7R4SPi #Neuroscience #DigitalBiomarkers #CNS #ClinicalDevelopment #HealthcareInnovation #Neurology #Psychiatry #MedicalResearch #DrugDevelopment #PatientCare #FutureOfMedicine #ClinicalTrials #HealthTech #Innovation #SherylCaswell

Exciting Findings on Ras-MAPK Pathway and White Matter Tracts! I am happy to share our latest publication in Brain Communications: "Impact of pathogenic variants of the Ras-Mitogen-activated protein kinase (Ras-MAPK) pathway on major white matter tracts in the human brain." Our study reveals critical insights into how Noonan syndrome (NS) and Neurofibromatosis type-1 (NF1), both linked to the Ras-MAPK pathway, affect white matter integrity in the developing brain. We observed that both NS and NF1 show similar yet distinct impacts on white matter, with NS having a more extensive effect. These findings highlight potential brain-focused outcome measures for treatments targeting this pathway. We are also deeply grateful to the RASopathies Network USA, Noonan Syndrom Foundation, and the Children's Tumor Foundation for their support. This work was made possible by funding from the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at Johns Hopkins University and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Institute of Child Health and Human Development, and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine . Read more here: 10.1093/braincomms/fcae274. #Research #Neuroscience #WhiteMatter #RasMAPK #NoonanSyndrome #NF1 #Stanford #BrainResearch"

Celebrated annually on March 26, Epilepsy Awareness Day, or Purple Day  - was created to increase the public’s understanding of this brain disorder and to eliminate the fear and stigma surrounding it. With over 3.5 million people diagnosed with epilepsy in the U.S. and over 50 million worldwide, it is likely you know someone living with the day-to-day challenges epilepsy brings. The good news is epilepsy can be easily managed if diagnosed and treated correctly, so awareness and research are important. At CTNx, we enable research by collaborating with neurologists to conduct clinical studies aimed at advancing epilepsy medicine and treatment choices. Get in touch with us today to discover how you can get involved in our epilepsy research. email: info@theCTNx.com Phone: (216) 538-1470  Web: www.theCTNx.com #epilepsy #neurology #treatmentoptions #clinicaltrials #clinicalresearch #clinicalstudy #neuroscience #brainhealth #awareness #braindisorders #neurologists #purpleday #awarenessday #epilepsyresearch

Stay updated on the latest in epilepsy research and management with the International Journal of Epilepsy (IJEP). Launched by the Indian Epilepsy Society, this peer-reviewed journal disseminates knowledge on prevention, diagnosis, treatment, and management of epilepsy. Directed at neurologists and related specialists, IJEP covers clinical neurology, neurosurgery, neuropsychiatry, neuropsychology, neuropharmacology, and epilepsy therapeutics. Indexed in Scopus, Embase, EBSCO, and ProQuest, this Open Access journal is available for free on Thieme E-Journals. https://lnkd.in/gz-zYMcm #EpilepsyResearch #Neurology #Neurosurgery #Neuropsychiatry #Neuropsychology #Neuropharmacology #Neuroimaging #EpilepsyTherapeutics #ClinicalNeurology #MedicalResearch #OpenAccess #PeerReviewed #IndianEpilepsySociety #NeurologicalDisorders #EpilepsyTreatment #EpilepsyCare #GlobalHealth #ThiemeEJournals #thiemeindia

"Many common neurological disorders are associated with advancing #ChronologicalAge, but their association with #BiologicalAge (BA) remains poorly understood." Here, Jonathan K L Mak, et al. "studied 325 870 participants in the UK Biobank without a diagnosed neurological condition at baseline and generated three previously-described measures of BA based on 18 routinely measured clinical biomarkers (PhenoAge, Klemera-Doubal method age (KDMAge), homeostatic dysregulation age)." "Using survival models, they assessed the effect of advanced BA on incident neurological diagnoses, including all-cause and cause-specific #Dementia, #IschaemicStroke, #ParkinsonsDisease and motor neuron disease." Learn More in BMJ Journals | Journal of Neurology, Neurosurgery & Psychiatry https://lnkd.in/d6HMcF8v Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank - Jonathan K L Mak, Chris McMurran, Sara Hägg Karolinska Institutet University of Cambridge